Company Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.

Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer.

The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer.

Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.

Country	United States
Founded	2018
IPO Date	Mar 19, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	Bronson Crouch

Contact Details

Address: 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 United States
Phone	972 499 3350
Website	instilbio.com

Stock Details

Ticker Symbol	TIL
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$20.00
CIK Code	1789769
CUSIP Number	45783C101
ISIN Number	US45783C2008
Employer ID	83-2072195
SIC Code	2836

Key Executives

Name	Position
Bronson Crouch	Chairman and Chief Executive Officer
Dr. Sandeep Laumas M.D.	Chief Financial Officer and Chief Business Officer

Latest SEC Filings

Date	Type	Title
Mar 27, 2026	S-8	Securities to be offered to employees in employee benefit plans
Mar 27, 2026	10-K	Annual Report
Mar 27, 2026	8-K	Current Report
Feb 9, 2026	SCHEDULE 13G/A	Filing
Jan 6, 2026	8-K	Current Report
Nov 13, 2025	10-Q	Quarterly Report
Nov 13, 2025	8-K	Current Report
Sep 10, 2025	144	Filing
Aug 13, 2025	10-Q	Quarterly Report
Aug 13, 2025	8-K	Current Report

View All SEC Filings